OncoMatch/Clinical Trials/NCT06840704
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
Is NCT06840704 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for non small cell lung cancer.
This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: thoracic radiotherapy
Lab requirements
Blood counts
anc ≥ 1.5 × 10^9/l; plt ≥ 80 × 10^9/l; hb ≥ 90 g/l
Kidney function
bun and cr ≤ 1.5 × uln, with creatinine clearance ≥ 50 ml/min (calculated using the cockcroft-gault formula)
Liver function
tbil ≤ 1.5 × uln; alt and ast ≤ 2 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify